News
-
-
-
-
-
-
PRESS RELEASE
Communiqué de presse : Le NEJM publie les données de phase III de l’étude XTEND-Kids montrant qu’ALTUVIIIO a le potentiel de transformer la prise en charge thérapeutique des enfants atteints d’hémophilie A sévère
Le NEJM publie les données de phase III de l'étude XTEND-Kids montrant qu'ALTUVIIIO a le potentiel de transformer la prise en charge thérapeutique des enfants atteints d'hémophilie A -
PRESS RELEASE
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data showing high-sustained factor levels with once-weekly dosing in children with severe hemophilia A, effective bleed protection, and no inhibitor development to factor VIII -
-
-
PRESS RELEASE
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
Positive phase 3 data of Dupixent in children aged 1-11 with eosinophilic esophagitis published in NEJM highlights significant histologic remission achieved and sustained improvements, potentially changing standard of care